ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Part of Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Youhe Medical Technology (Beijing) Co. Ltd. (doing business as Eucure Biopharma) is a company headquartered in Beijing, China. The firm engages in discovery and development immuno-oncology targeted antibodies. Da Yao Zhao is currently the CEO of the company. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. acquired Youhe Medical Technology (Beijing) Co. Ltd. on August 31, 2020.\nThe company says this about itself: Eucure Biopharma is a biotechnology company with rich experience in new drug discovery and clinical development. Eucure focuses on the development of innovative antibody drugs with independent intellectual property rights. Leveraging cooperative development and strong clinical assets, Eucure Biopharma has built a strong preclinical and clinical pipeline for over ten targets. Currently, two products have received clinical trial approvals in the US and China. In Australia, three products have entered Phase I clinical stages.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

Ercole Biotech, Inc., a research stage biopharmaceutical company, creates oligonucleotide drugs that achieve their therapeutic effect by directing the alternative splicing of target genes. The company was founded in 2002 and is based in Research Triangle Park, North Carolina. As of March 20, 2008, Ercole Biotech, Inc. operates as a subsidiary of AVI Biopharma, Inc.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.